Human Glypican 3 quantitates human Glypican 3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Glypican 3.
Human Glypican 3 quantitates human Glypican 3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Glypican 3.
Human Glypican 3 quantitates human Glypican 3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Glypican 3.
GPC3 is a cellular surface proteoglycan containing d-heparane sulphate. This protein can be involved in suppressing/modulating growth in mainly mesodermal tissues and organs and can play a role in modulation of IGF2 interactions with its receptor and thus modulate its function. Glypican-bound integral membrane proteoglycans contain a cytoplasmic membrane-based nucleus protein via glycosyl phosphatidylinositol (GPI) binding. These proteins can play a role in controlling cell division, growth regulation and tumour predisposition. Deletion mutations in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS), also known as Simpson's Dysmorphic Syndrome (SDYS). The SGBS is a pathology characterized by an advance in pre- and postnatal growth (gigantism) with visceral and skeletal abnormalities.
Sensitivity
Sensitivity of dosage: 0.8 ng/mL.
Measurement range
Dose range: 0.8 to 600 ng/mL.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Target
Target: Glypican 3.
Samples
Type of sample: Plasma, Serum, Surnatant (surnatant volume, 50 µl; plasma, 50 µl; serum, 50 µl).